Literature DB >> 19367258

A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.

Hua Li1, Shih-Wen Lin, Wynetta Giles-Davis, Yan Li, Dongming Zhou, Zhi Quan Xiang, Katherine A High, Hildegund C J Ertl.   

Abstract

Hepatic adeno-associated virus (AAV)-serotype 2-mediated gene transfer results in sustained transgene expression in experimental animals but not in human subjects. We hypothesized that loss of transgene expression in humans might be caused by immune memory mechanisms that become reactivated upon AAV vector transfer. Here, we tested the effect of immunological memory to AAV capsid on AAV-mediated gene transfer in a mouse model. Upon hepatic transfer of an AAV2 vector expressing human factor IX (hF.IX), mice immunized with adenovirus (Ad) vectors expressing AAV8 capsid before AAV2 transfer developed less circulating hF.IX and showed a gradual loss of hF.IX gene copies in liver cells as compared to control animals. This was not observed in mice immunized with an Ad vectors expressing AAV2 capsid before transfer of rAAV8-hF.IX vectors. The lower hF.IX expression was primarily linked to AAV-binding antibodies that lacked AAV-neutralizing activity in vitro rather than to AAV capsid-specific CD8(+) T cells.

Entities:  

Mesh:

Year:  2009        PMID: 19367258      PMCID: PMC2835197          DOI: 10.1038/mt.2009.79

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

1.  Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.

Authors:  D D Koeberl; I E Alexander; C L Halbert; D W Russell; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

Authors:  Z Q Xiang; Y Yang; J M Wilson; H C Ertl
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

3.  Critical contribution of liver natural killer T cells to a murine model of hepatitis.

Authors:  K Takeda; Y Hayakawa; L Van Kaer; H Matsuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.

Authors:  Jane D Mount; Roland W Herzog; D Michael Tillson; Susan A Goodman; Nancy Robinson; Mark L McCleland; Dwight Bellinger; Timothy C Nichols; Valder R Arruda; Clinton D Lothrop; Katherine A High
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

5.  Identification of mouse AAV capsid-specific CD8+ T cell epitopes.

Authors:  Denise E Sabatino; Federico Mingozzi; Daniel J Hui; Haifeng Chen; Peter Colosi; Hildegund C J Ertl; Katherine A High
Journal:  Mol Ther       Date:  2005-11-02       Impact factor: 11.454

6.  Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

Authors:  Dirk Grimm; Shangzhen Zhou; Hiroyuki Nakai; Clare E Thomas; Theresa A Storm; Sally Fuess; Takashi Matsushita; James Allen; Richard Surosky; Michael Lochrie; Leonard Meuse; Alan McClelland; Peter Colosi; Mark A Kay
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

7.  Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.

Authors:  William M Siders; Jacqueline Shields; Johanne Kaplan; Michael Lukason; Lisa Woodworth; Sam Wadsworth; Abraham Scaria
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

8.  Role of dendritic cells in antibody-dependent enhancement of dengue virus infection.

Authors:  Kobporn Boonnak; Bonnie M Slike; Timothy H Burgess; Randall M Mason; Shuenn-Jue Wu; Peifang Sun; Kevin Porter; Irani Fianza Rudiman; Djoko Yuwono; Pilaipan Puthavathana; Mary A Marovich
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

Review 9.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

10.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

View more
  24 in total

1.  Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.

Authors:  Hua Li; Steven Tuyishime; Te-Lang Wu; Wynetta Giles-Davis; Dongming Zhou; Weidong Xiao; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

2.  Capsid antibodies to different adeno-associated virus serotypes bind common regions.

Authors:  Brittney L Gurda; Michael A DiMattia; Edward B Miller; Antonette Bennett; Robert McKenna; Wendy S Weichert; Christian D Nelson; Wei-jun Chen; Nicholas Muzyczka; Norman H Olson; Robert S Sinkovits; John A Chiorini; Sergei Zolotutkhin; Olga G Kozyreva; R Jude Samulski; Timothy S Baker; Colin R Parrish; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

3.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Authors:  Ashley T Martino; Etiena Basner-Tschakarjan; David M Markusic; Jonathan D Finn; Christian Hinderer; Shangzhen Zhou; David A Ostrov; Arun Srivastava; Hildegund C J Ertl; Cox Terhorst; Katherine A High; Federico Mingozzi; Roland W Herzog
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

4.  Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.

Authors:  L Samaranch; P Hadaczek; A P Kells; J R Bringas; D Stockinger; W San Sebastian; M Macayan; S Samineni; P Pivirotto; J Forsayeth; K S Bankiewicz
Journal:  Gene Ther       Date:  2015-08-23       Impact factor: 5.250

Review 5.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

Review 6.  Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Authors:  Wolfgang Poller; Roger Hajjar; Heinz-Peter Schultheiss; Henry Fechner
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

7.  Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.

Authors:  David M Markusic; Roland W Herzog
Journal:  J Genet Syndr Gene Ther       Date:  2012-01-18

8.  The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer.

Authors:  ZhiQuan Xiang; Raj K Kurupati; Yan Li; Klaudia Kuranda; Xiangyang Zhou; Federico Mingozzi; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2019-11-21       Impact factor: 11.454

9.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

10.  Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery.

Authors:  Louise R Rodino-Klapac; Chrystal L Montgomery; William G Bremer; Kimberly M Shontz; Vinod Malik; Nancy Davis; Spencer Sprinkle; Katherine J Campbell; Zarife Sahenk; K Reed Clark; Christopher M Walker; Jerry R Mendell; Louis G Chicoine
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.